Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Optimising first-line treatment for metastatic renal cell carcinoma.

de Velasco G.

Lancet. 2020 Jan 18;395(10219):e7. doi: 10.1016/S0140-6736(19)32495-X. No abstract available.

PMID:
31954470
2.

Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC.

Clin Genitourin Cancer. 2019 Dec 13. pii: S1558-7673(19)30380-5. doi: 10.1016/j.clgc.2019.12.007. [Epub ahead of print]

PMID:
31926879
3.

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma.

Carril-Ajuria L, Santos M, Roldán-Romero JM, Rodriguez-Antona C, de Velasco G.

Cancers (Basel). 2019 Dec 19;12(1). pii: E16. doi: 10.3390/cancers12010016. Review.

4.

Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.

Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC.

Eur Urol Oncol. 2019 Nov 27. pii: S2588-9311(19)30160-9. doi: 10.1016/j.euo.2019.11.001. [Epub ahead of print]

PMID:
31786162
5.

Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma.

Carretero-González A, Salamanca Santamaría J, Castellano D, de Velasco G.

Medicine (Baltimore). 2019 Nov;98(47):e18098. doi: 10.1097/MD.0000000000018098.

6.

Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1.

Lorente M, García-Casas A, Salvador N, Martínez-López A, Gabicagogeascoa E, Velasco G, López-Palomar L, Castillo-Lluva S.

J Cell Sci. 2019 Oct 22;132(20). pii: jcs234120. doi: 10.1242/jcs.234120.

7.

Renal length and volume prediction in healthy children.

Bianchi ME, Forlino D, Velasco GA, Rodriguez PO, López G, Cusumano AM.

Clin Nephrol. 2019 Aug 26. doi: 10.5414/CNP92S105. [Epub ahead of print]

PMID:
31448721
8.

First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.

Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T, Bjarnason GA, Choueiri TK, Heng DYC.

Eur Urol. 2019 Dec;76(6):861-867. doi: 10.1016/j.eururo.2019.07.048. Epub 2019 Aug 22.

PMID:
31445844
9.

Life History Parameters of Genypterus brasiliensis (Teleostei: Ophidiidae), an Endemic Fisheries Resource of the Southwestern Atlantic.

Tomás ARG, Eleuterio CLT, Velasco G.

An Acad Bras Cienc. 2019 Aug 12;91(3):e20170793. doi: 10.1590/0001-3765201920170793.

10.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B.

Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Review.

PMID:
31377308
11.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Sep;119:200-201. doi: 10.1016/j.ejca.2019.04.012. Epub 2019 Jul 11. No abstract available.

PMID:
31301937
12.

Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

Segovia C, San José-Enériz E, Munera-Maravilla E, Martínez-Fernández M, Garate L, Miranda E, Vilas-Zornoza A, Lodewijk I, Rubio C, Segrelles C, Valcárcel LV, Rabal O, Casares N, Bernardini A, Suarez-Cabrera C, López-Calderón FF, Fortes P, Casado JA, Dueñas M, Villacampa F, Lasarte JJ, Guerrero-Ramos F, de Velasco G, Oyarzabal J, Castellano D, Agirre X, Prósper F, Paramio JM.

Nat Med. 2019 Jul;25(7):1073-1081. doi: 10.1038/s41591-019-0499-y. Epub 2019 Jul 3.

PMID:
31270502
13.

Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Otero I, López F, Castellano D, de Velasco G.

Oncotarget. 2019 May 14;10(35):3294-3301. doi: 10.18632/oncotarget.26908. eCollection 2019 May 14.

14.

Genomic epidemiology of Neisseria meningitidis serogroup W in Switzerland between 2010 and 2016.

Leo S, Lazarevic V, Girard M, Velasco GCG, Anson L, Gaïa N, Renzi G, Cherkaoui A, Born R, Basler S, Schrenzel J.

J Infect. 2019 Sep;79(3):277-287. doi: 10.1016/j.jinf.2019.05.014. Epub 2019 May 21. No abstract available.

PMID:
31125638
15.

Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.

Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A.

Clin Transl Oncol. 2019 Oct;21(10):1413-1423. doi: 10.1007/s12094-019-02070-6. Epub 2019 Mar 15.

PMID:
30877636
16.

Withdrawal: Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins.

Velasco G, Cal S, Quesada V, Sánchez LM, López-Otín C.

J Biol Chem. 2019 Jan 25;294(4):1430. doi: 10.1074/jbc.W118.007324. No abstract available.

17.

Update on the management of patients with intermediate and poor-risk testicular germ cell tumors and new biological insights.

Mérida-García A, Díaz-Serrano A, Bernard B, Del Mar Galera M, de Velasco G, Sepúlveda JM, Fernández L, Medina J, Castellano D.

Cancer Treat Res Commun. 2019;19:100117. doi: 10.1016/j.ctarc.2018.100117. Epub 2018 Dec 30. Review. No abstract available.

PMID:
30684681
18.

Challenges of treatment selection in the older prostate patient.

Carretero González A, Martín MC, Luyo M, Castellano D, de Velasco G.

J Geriatr Oncol. 2019 Jul;10(4):666-668. doi: 10.1016/j.jgo.2019.01.009. Epub 2019 Jan 20. No abstract available.

PMID:
30674419
19.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Erratum in: Eur J Cancer. 2019 Sep;119:200-201.

PMID:
30616146
20.

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).

González Del Alba A, De Velasco G, Lainez N, Maroto P, Morales-Barrera R, Muñoz-Langa J, Pérez-Valderrama B, Basterretxea L, Caballero C, Vazquez S.

Clin Transl Oncol. 2019 Jan;21(1):64-74. doi: 10.1007/s12094-018-02001-x. Epub 2018 Dec 18.

21.

Genetics meets DNA methylation in rare diseases.

Velasco G, Francastel C.

Clin Genet. 2019 Feb;95(2):210-220. doi: 10.1111/cge.13480. Epub 2018 Dec 18. Review.

PMID:
30456829
22.

Phosphorylation of FOXO Proteins as a Key Mechanism to Regulate Their Activity.

Orea-Soufi A, Dávila D, Salazar-Roa M, de Mar Lorente M, Velasco G.

Methods Mol Biol. 2019;1890:51-59. doi: 10.1007/978-1-4939-8900-3_5.

PMID:
30414144
23.

Mouse Models to Disentangle the Hallmarks of Human Aging.

Folgueras AR, Freitas-Rodríguez S, Velasco G, López-Otín C.

Circ Res. 2018 Sep 14;123(7):905-924. doi: 10.1161/CIRCRESAHA.118.312204.

PMID:
30355076
24.

Genome Sequencing and Analysis Methods in Chronic Lymphocytic Leukemia.

Quesada V, Araujo-Voces M, Pérez-Silva JG, Velasco G, López-Otín C.

Methods Mol Biol. 2019;1881:319-325. doi: 10.1007/978-1-4939-8876-1_22.

PMID:
30350214
25.

The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function.

Caravia XM, Fanjul V, Oliver E, Roiz-Valle D, Morán-Álvarez A, Desdín-Micó G, Mittelbrunn M, Cabo R, Vega JA, Rodríguez F, Fueyo A, Gómez M, Lobo-González M, Bueno H, Velasco G, Freije JMP, Andrés V, Ibáñez B, Ugalde AP, López-Otín C.

PLoS Biol. 2018 Oct 22;16(10):e2006247. doi: 10.1371/journal.pbio.2006247. eCollection 2018 Oct.

26.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12.

PMID:
30341028
27.

Specific combinations of biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome.

Paolacci S, Li Y, Agolini E, Bellacchio E, Arboleda-Bustos CE, Carrero D, Bertola D, Al-Gazali L, Alders M, Altmüller J, Arboleda G, Beleggia F, Bruselles A, Ciolfi A, Gillessen-Kaesbach G, Krieg T, Mohammed S, Müller C, Novelli A, Ortega J, Sandoval A, Velasco G, Yigit G, Arboleda H, Lopez-Otin C, Wollnik B, Tartaglia M, Hennekam RC.

J Med Genet. 2018 Dec;55(12):837-846. doi: 10.1136/jmedgenet-2018-105528. Epub 2018 Oct 15.

PMID:
30323018
28.

CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome.

Unoki M, Funabiki H, Velasco G, Francastel C, Sasaki H.

J Clin Invest. 2019 Jan 2;129(1):78-92. doi: 10.1172/JCI99751. Epub 2018 Nov 19.

29.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

30.

CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status.

Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM.

Clin Cancer Res. 2019 Jan 1;25(1):390-402. doi: 10.1158/1078-0432.CCR-18-0685. Epub 2018 Sep 21.

31.

Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.

López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, Velasco G.

Biochem Pharmacol. 2018 Nov;157:266-274. doi: 10.1016/j.bcp.2018.09.007. Epub 2018 Sep 7.

32.

Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.

López-Valero I, Torres S, Salazar-Roa M, García-Taboada E, Hernández-Tiedra S, Guzmán M, Sepúlveda JM, Velasco G, Lorente M.

Biochem Pharmacol. 2018 Nov;157:275-284. doi: 10.1016/j.bcp.2018.08.023. Epub 2018 Aug 18.

PMID:
30125556
33.

Subtelomeric methylation distinguishes between subtypes of Immunodeficiency, Centromeric instability and Facial anomalies syndrome.

Toubiana S, Velasco G, Chityat A, Kaindl AM, Hershtig N, Tzur-Gilat A, Francastel C, Selig S.

Hum Mol Genet. 2018 Oct 15;27(20):3568-3581. doi: 10.1093/hmg/ddy265.

PMID:
30010917
34.

Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK.

Eur J Surg Oncol. 2018 Sep;44(9):1439-1445. doi: 10.1016/j.ejso.2018.05.026. Epub 2018 Jun 5.

PMID:
29935840
35.

[Prevalence of obesity and arterial hypertension and their relationship with age and gender in the city of Resistencia, Argentina, in the years 2008-2014].

Bianchi MEV, Cusumano AM, Torres C, Rojas NG, Velasco GA.

Hipertens Riesgo Vasc. 2019 Jan - Mar;36(1):14-20. doi: 10.1016/j.hipert.2018.04.003. Epub 2018 May 17. Spanish.

PMID:
29779987
36.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

37.

Exosomes: Definition, Role in Tumor Development and Clinical Implications.

Carretero-González A, Otero I, Carril-Ajuria L, de Velasco G, Manso L.

Cancer Microenviron. 2018 Jun;11(1):13-21. doi: 10.1007/s12307-018-0211-7. Epub 2018 May 3. Review.

38.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

39.

Comparative methylome analysis of ICF patients identifies heterochromatin loci that require ZBTB24, CDCA7 and HELLS for their methylated state.

Velasco G, Grillo G, Touleimat N, Ferry L, Ivkovic I, Ribierre F, Deleuze JF, Chantalat S, Picard C, Francastel C.

Hum Mol Genet. 2018 Jul 15;27(14):2409-2424. doi: 10.1093/hmg/ddy130.

PMID:
29659838
40.

Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.

Folgueras AR, Freitas-Rodríguez S, Ramsay AJ, Garabaya C, Rodríguez F, Velasco G, López-Otín C.

Nat Commun. 2018 Apr 10;9(1):1350. doi: 10.1038/s41467-018-03853-1.

41.

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.

Carretero-González A, Lora D, Ghanem I, Zugazagoitia J, Castellano D, Sepúlveda JM, López-Martin JA, Paz-Ares L, de Velasco G.

Oncotarget. 2018 Jan 20;9(9):8706-8715. doi: 10.18632/oncotarget.24283. eCollection 2018 Feb 2.

42.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

43.

The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR.

Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.

PMID:
29361425
44.

Cancer Susceptibility Models in Protease-Deficient Mice.

Folgueras AR, Freitas-Rodríguez S, Español Y, Velasco G.

Methods Mol Biol. 2018;1731:235-245. doi: 10.1007/978-1-4939-7595-2_21.

PMID:
29318558
45.

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Sun M, De Velasco G, Brastianos PK, Aizer AA, Martin A, Moreira R, Nguyen PL, Trinh QD, Choueiri TK.

Eur Urol Focus. 2019 May;5(3):474-481. doi: 10.1016/j.euf.2017.12.007. Epub 2018 Jan 5.

PMID:
29311016
46.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

47.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA.

Oncotarget. 2017 Aug 8;8(48):84572-84578. doi: 10.18632/oncotarget.20028. eCollection 2017 Oct 13. Review.

48.

Adaptive Evolution under Extreme Genetic Drift in Oxidatively Stressed Caenorhabditis elegans.

Christy SF, Wernick RI, Lue MJ, Velasco G, Howe DK, Denver DR, Estes S.

Genome Biol Evol. 2017 Nov 1;9(11):3008-3022. doi: 10.1093/gbe/evx222.

49.

In Reply.

de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK.

Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. No abstract available.

50.

TMJ symptoms reduce chewing amplitude and velocity, and increase variability.

Radke JC, Kamyszek GJ, Kull RS, Velasco GR.

Cranio. 2019 Jan;37(1):12-19. doi: 10.1080/08869634.2017.1365421. Epub 2017 Sep 4.

PMID:
28868987

Supplemental Content

Loading ...
Support Center